NCT02048709View on ClinicalTrials.gov

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Solid Tumor
Interventions
DRUG

GDC-0919

Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle

Trial Locations (1)

30912

Georgia Regents University, Augusta

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY